金黄色葡萄球菌肠毒素A对H22小鼠移植瘤的抑制作用

旨在探讨金黄色葡萄球菌肠毒素A(SEA)在KM鼠体内的抑瘤效果.建立H22荷瘤小鼠模型,将20只小鼠随机分为对照组(生理盐水)、低剂量组(15 μg/ml)、中剂量组(25 μg/ml)和高剂量组(50 μg/ml),观察肿瘤生长趋势,计算抑瘤率,通过ELISA检测IL-2的含量.结果显示,给药组肿瘤生长趋势均较对照组缓慢;对照组、低剂量组、中剂量组、高剂量组的抑瘤率分别为0,28.9%,34.0%,51.0%(P<0.05);血清中IL-2含量分别为58.9 pg/ml、83.6 pg/ml、91.8 pg/ml、118.1 pg/ml.金黄色葡萄球菌肠毒素A(SEA)可抑制H22肿瘤的生长,并上调IL-2的分泌.     

山野木层孔菌子实体中抑制H22荷瘤小鼠肿瘤的活性成分研究

采用梯度提取法对山野木层孔菌子实体进行提取,得到石油醚层、甲醇层及水层3 种提取物及石油醚层中获得化合物4,6,8(14),22(23)-四烯-3-酮-麦角甾烷,并采用H22 荷瘤小鼠进行体内抗肿瘤活性研究,以抑瘤率、免疫器官指数、免疫因子为指标检测抗肿瘤活性。结果表明,石油醚高剂量组（100mg/kg）、单体化合物中剂量组（7.5mg/kg）抑制率分别为62.21%、57.67%;脾指数、胸腺指数均高于对照组和环磷酰胺（CTX）组,白介素-2（IL-2）的含量明显高于对照组和环磷酰胺（CTX）组（P＜0.01）;肿瘤坏死因子-α（TNF-α）含量明显低于对照组（P＜0.01）。因此认为上述石油醚提取物和单体化合物对H22荷瘤小鼠肿瘤有抑制作用,并且均能改善小鼠的免疫功能。     

芪胶升白胶囊联合环磷酰胺对S_(180)荷瘤小鼠增效减毒作用研究

本文探讨芪胶升白胶囊(QSC)与环磷酰胺(CTX)联合应用对S_(180)荷瘤小鼠的增效减毒作用。造荷S_(180)肿瘤小鼠模型,60只荷瘤小鼠随机分为5组:模型组,CTX(30 mg/kg)组,CTX+QSC低、中、高剂量(0.5、1.0、2.0 g/kg)组。每日测量小鼠体重和肿瘤体积,分别连续给药15 d后,测小鼠血细胞计数,脏器指数和抑瘤率,HE染色法观察肿瘤组织形态,Annexin V/PI双染流式术测定肿瘤组织细胞的凋亡率。实验结果显示与CTX组比较,联合用药各剂量组的小鼠肿瘤体积均较小,抑瘤率以及肿瘤细胞凋亡率均有提高,胸腺、脾脏指数也较高,联合用药高剂量组白细胞计数增高统计学意义显著(P0.01),镜下观察肿瘤组织坏死明显,表明QSC与CTX联合使用对S_(180)荷瘤小鼠有一定的增效减毒作用。     

凹顶藻萜类化合物对小鼠H22肿瘤生长及VEGF、PCNA表达的影响

目的:观察凹项藻提取物(Laurenciaterpenoid extract,LET)对接种H22细胞小鼠的肿瘤生长及血管内皮细胞生长因子(VEGF)、增殖细胞核抗原(PCNA)表达的影响.方法:昆明小鼠随机分为5组(10只,组),即模型组、LET低中高剂量组(25、50、100 mg/kg·d-1)、环磷酰胺组(CTX对照组).各组小鼠左前腋下皮下接种H22肝癌细胞,第二天除模型组外,其余4组分别以不同剂量的LET、CTX灌胃,于15天后处死,完整剥离出肿瘤,称重,计算抑瘤率.免疫组化法测定肿瘤组织中VEGF、PCNA的表达.结果:LET低、中、高剂量组小鼠H22肿瘤质量增长均较模型组缓慢(P<0.05),抑瘤率分别为27.5%、34.9%、41.4%;同时LET中、高剂量组VEGF阳性表达较模型组显著减少(P<0.05),低剂量组未见明显变化,但LET各剂量组PCNA阳性表达较模型组显著减少(P<0.05).结论:LET各剂量组可以抑制小鼠H22肿瘤的生长,具有较高的抑瘤活性,且中、高剂量组能抑制VEGF的表达(P<0.05),低、中、高剂量组能抑制PCNA的表达(P<0.05).LET对肿瘤组织VEGF、PCNA表达的抑制作用可能是其抗H22肿瘤及抗血管生成的一个重要原因.     

硬枝树花中抑制H_22荷瘤小鼠肿瘤的活性成分研究

研究了从硬枝树花中提取得到的4个单体化合物松萝酸(usnic acid)、去甲环萝酸(evernic acid)、巴尔巴地衣酸(barbatic acid)和水杨嗪酸(salazinic acid)对H22荷瘤小鼠的抑瘤作用,并且对抑瘤率、胸腺指数、脾指数及小鼠白介素-2含量等各个指标的进行检测,以说明此4种化合物对小鼠肿瘤生长的抑制效果。结果表明,松萝酸高、中剂量组,去甲环萝酸高、中剂量组,巴尔巴地衣酸低剂量组,水杨嗪酸高剂量组对小鼠肿瘤有较好的抑制效果,与阴性对照组比较有极显著差异(P0.01),并且这些组的H22荷瘤小鼠血清中白介素-2的含量显著增加,与抑制肿瘤活性具有相关性。     

重组别藻蓝蛋白(rAPC)抑瘤活性及其对免疫作用的研究(英文)

目的:观察重组别藻蓝蛋白(rAPC)对接种H22肝癌细胞小鼠的抑瘤活性及其免疫作用。方法:昆明小鼠随机分为5组(10只/组),即模型组、rAPC低、中、高剂量组(25,50,100mg/kg·d)、环磷酰胺组(CY对照组)。建立小鼠肝癌H22移植瘤模型,次日除模型组外,其余4组分别以不同剂量的rAPC、CY灌胃,于15d后处死,完整剥离出肿瘤、胸腺、脾脏,准确称重,计算抑瘤率、胸腺指数和脾指数,并采用放免法(RIA)测定血清中白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)的水平。结果:rAPC低剂量组小鼠H22肿瘤质量增长较模型组缓慢(P<0.05),中、高剂量组较模型组显著缓慢(P<0.01),抑瘤率分别为25.2%、36.7%、43.1%;rAPC各剂量组能升高胸腺指数、脾指数和血清中细胞因子IL-6、TNF-α的水平。结论:rAPC可有效抑制H22肝癌的生长,促进小鼠胸腺和脾脏的生长发育,提高小鼠的免疫功能,从而抑制肿瘤的生长。     

广叶绣球菌超微粉抗肿瘤作用研究

广叶绣球菌(荷仙菇-H)是近年来新培养的一种食药用真菌,属担子菌门、多孔菌目、绣球菌科、绣球菌属。本文对其超微粉的抗肿瘤作用及机制进行了研究。建立了H22荷瘤小鼠肿瘤移植模型,设置空白对照组、模型组、环磷酰胺阳性组、广叶绣球菌超微粉高、中、低3个剂量组(1 000,500和100mg/kg),连续给予相应药物10d,计算H22荷瘤小鼠的抑瘤率、体质量、胸腺指数、脾脏指数以及肝脏指数,对各组小鼠的瘤块进行组织病理学研究,并对血清中的SOD和IFN-γ含量进行了测定。结果发现广叶绣球菌超微粉3个给药组的抑瘤率均大于40%,高剂量组抑瘤率最高为54%;可增加小鼠体质量;提高胸腺指数、脾脏指数和肝脏指数;给药组SOD值均高于模型组,说明广叶绣球菌超微粉可以起到抗氧化的作用;给药组IFN-γ值均高于模型组,给药组VEGF值均低于模型组,说明广叶绣球菌超微粉能够提高机体免疫能力。因此,广叶绣球菌超微粉的抗肿瘤作用明显,可能是通过改善机体免疫功能和抗氧化能力,抑制了肿瘤细胞,达到抗肿瘤的功效。     

秀珍菇粉对H22荷瘤小鼠体内抗肿瘤作用研究

目的本试验旨在研究秀珍菇抗肿瘤作用及其抑瘤机制。方法选用ICR雄性小鼠60只,取10只作为空白组,剩余50只小鼠通过腋部皮下接种H22小鼠腹水构建荷瘤小鼠模型,造模后随机分为模型组、阳性药(CTX)组、秀珍菇低、中、高剂量组,每组10只。模型组小鼠灌服生理盐水,阳性药组小鼠按20 mg/kg体重隔天腹腔注射注射环磷酰胺(CTX)生理盐水溶液,秀珍菇低、中、高剂量组小鼠分别按750、1500、3000 mg/kg体重每天剂量灌服秀珍菇生理盐水混悬液。给药10 d后,测定各组小鼠平均瘤重,肿瘤抑制率;测定免疫器官脏器指数、血清免疫球蛋白和细胞因子含量;测定肝、肾抗氧化指标;观察肿瘤和脾组织HE染色病理切片。结果 (1) CTX及秀珍菇低、中、高剂量组小鼠的平均瘤重均极显著低于模型组(P0. 01),四组小鼠肿瘤抑制率分别为55. 18%,29. 06%、47. 47%和48. 80%。(2)与空白组比较,模型组小鼠脾指数、血清Ig A和TNF-α含量及肝MDA含量显著升高(P0. 05,P0. 01),血清IL-6含量有上升趋势(P 0. 05),而血清IL-2含量、肝CAT和GSH-Px活性及肾SOD、GSH-Px和CAT活性显著降低(P0. 05,P0. 01);同时,CTX组小鼠胸腺指数显著低于空白组(P0. 05)。(3)秀珍菇对荷瘤小鼠免疫和抗氧化功能异常改变具有逆转作用:与模型组比较,秀珍菇各剂量组小鼠血清Ig A和TNF-α含量及高剂量组小鼠IL-6水平显著降低(P 0. 05,P 0. 01),低剂量组小鼠血清IL-2水平显著升高(P 0. 01);秀珍菇处理还显著提高了各剂量组荷瘤小鼠肝CAT活性及肾SOD和CAT活性(P 0. 05,P 0. 01),显著升高中、高剂量组肝GSH-Px活性和低、中剂量组肾GSH-Px活性(P 0. 05,P 0. 01),并显著降低中剂量组的肝MDA含量(P 0. 05)。(4)与CTX组比较,秀珍菇高剂量组小鼠脾指数显著提高(P 0. 05),而血清IL-6水平显著降低(P 0. 05)。(5)肿瘤组织病理切片显示CTX组和秀珍菇各剂量组的肿瘤坏死面积明显增加。结论秀珍菇可抑制H22实体移植瘤生长,其机制与其具有较强的免疫调节和抗氧化作用有关。     

重组别藻蓝蛋(rAPC)抑瘤活性及其对免疫作用的研究

目的:观察重组别藻蓝蛋白(rAPC)对接种H22肝癌细胞小鼠的抑瘤活性及其免疫作用.方法:昆明小鼠随机分为5组(10只/组),即模型组、rAPC低、中、高剂量组(25,50,100mg/kg·d)、环磷酰胺组(CY对照组).建立小鼠肝癌1422移植瘤模型,次日除模型组外,其余4组分别以不同剂量的rAPe、CY灌胃,于15d后处死,完整剥离出肿瘤、胸腺、脾脏,准确称重,计算抑瘤率、胸腺指数和脾指数,并采用放免法(PIA)测定血清中白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)的水平.结果:rAPC低剂量组小鼠H22肿瘤质量增长较模型组缓慢(P＜0.05),中、高剂量组较模型组显著缓慢(P＜0.01),抑瘤率分别为25.2%、36.7%、43.1%;rAPC各剂量组能升高胸腺指数、脾指数和血清中细胞因子IL-6、TNF-α的水平.结论:rAPC可有效抑制H22肝癌的生长,促进小鼠胸腺和脾脏的生长发育,提高小鼠的免疫功能,从而抑制肿瘤的生长.     

银耳多糖对D-半乳糖致衰老模型小鼠抗氧化能力的影响

研究了银耳多糖对D-半乳糖致衰老模型小鼠抗氧化能力影响。将ICR小鼠腹腔注射D-半乳糖建立衰老模型,同时给予不同剂量的银耳多糖(TP),8周后获取小鼠心、脑,测定超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)活力以及丙二醛(MDA)含量的差异。结果:TP各剂量组SOD和GSH-Px活力高于对照组(P<0.05),且高剂量组SOD、GSH-Px活力均高于低剂量和中剂量组(P<0.05);中、高剂量TP组MDA含量低于对照组(P<0.05)且高剂量组MDA含量低于低剂量组(P<0.05)。结论:银耳多糖对于衰老模型小鼠抗氧化能力具有一定正性调节作用。     

顺铂联合VEGF抗体对食管癌移植瘤小鼠免疫调节以及癌细胞增殖和肺转移的影响

摘要 目的：研究顺铂联合血管内皮生长因子（vascular endothelial growth factor,VEGF）治疗对食管癌移植瘤小鼠免疫功能、癌细胞增殖以及肺转移的影响。方法：30只BALB/c小鼠通过皮下注射食管癌移植瘤模型。一周后,30只食管癌移植瘤模型小鼠被随机均分为3组,即模型组、顺铂组和联合组。模型组不进行治疗,顺铂组腹腔注顺铂治疗,联合组腹腔注射顺铂联合尾静脉注射VEGF抗体进行治疗,共治疗7周。比较各组小鼠体重,食管癌移植瘤体积和重量,卵巢癌细胞肺组织转移结节数、癌细胞转移面积和转移病灶总数,以及食管癌移植瘤外周血CD4⁺、CD8⁺以及CD4⁺/CD8⁺ T淋巴细胞比例。结果：（1）顺博组和联合组小鼠体重均显著高于对照组,而联合组小鼠体重显著高于顺铂组（P<0.05）;（2）顺铂组和联合组小鼠CD4+和CD8+细胞比例均显著低于对照组（P<0.05）,而CD4⁺/CD8⁺却显著高于对照组（P<0.05）;（3）联合组小鼠CD4⁺和CD8⁺细胞比例均显著高于对照组（P<0.05）,而CD4⁺/CD8⁺却显著低于顺铂组（P<0.05）;（4）顺铂组和联合组小鼠食管癌肿瘤组织体积和重量,肺转移结节数、转移面积和转移病灶数均显著低于对照组（P<0.05）,而联合组小鼠显著低于顺铂组（P<0.05）。结论：VEGF抗体可以显著增强顺铂在体内对食管癌的抗癌特性,并有助于增强食管癌移植瘤小鼠免疫功能、抑制癌细胞体内增殖和肺部转移。     

Effective Chemoimmunotherapy with Anti-TGFβ Antibody and Cyclophosphamide in a Mouse Model of Breast Cancer

TGFβ is reportedly responsible for accumulation of CD4⁺Foxp3⁺ regulatory T cells (Tregs) in tumor. Thus, we treated mouse 4T1 mammary carcinoma with 1D11, a neutralizing anti-TGFβ (1,2,3) antibody. The treatment delayed tumor growth, but unexpectedly increased the proportion of Tregs in tumor. In vitro, 1D11 enhanced while TGFβ potently inhibited the proliferation of Tregs. To enhance the anti-tumor effects, 1D11 was administered with cyclophosphamide which was reported to eliminate intratumoral Tregs. This combination resulted in long term tumor-free survival of up to 80% of mice, and the tumor-free mice were more resistant to re-challenge with tumor. To examine the phenotype of tumor infiltrating immune cells, 4T1-tumor bearing mice were treated with 1D11 and a lower dose of cyclophosphamide. This treatment markedly inhibited tumor growth, and was accompanied by massive infiltration of IFNγ-producing T cells. Furthermore, this combination markedly decreased the number of splenic CD11b⁺Gr1⁺ cells, and increased their expression levels of MHC II and CD80. In a spontaneous 4T1 lung metastasis model with resection of primary tumor, this combination therapy markedly increased the survival of mice, indicating it was effective in reducing lethal metastasis burden. Taken together, our data show that anti-TGFβ antibody and cyclophosphamide represents an effective chemoimmunotherapeutic combination.     

肝癌小鼠外周血及脾脏T淋巴细胞亚群的变化及其意义

目的:观察小鼠原位肝癌模型外周血以及脾脏T淋巴细胞亚群与正常小鼠之间的差异变化,探讨其差异变化的意义。方法:在正常KM小鼠肝脏种植H22细胞,建立小鼠原位模型。采用流式细胞术,以健康正常小鼠为对照,检测肝癌小鼠外周血以及脾脏T淋巴细胞亚群的变化。结果:与健康正常小鼠相比,肝癌小鼠外周血CD4~+T淋巴细胞、CD4~+/CD8~+比例有显著性降低,CD8~+T淋巴细胞显著性升高;脾脏CD3~+、CD4~+T淋巴细胞有显著性降低。结论:小鼠原位肝癌模型外周血以及脾脏T淋巴细胞亚群发生异常,免疫系统紊乱,可以反映小鼠肝癌的发生、发展。     

新加良附方对移植性小鼠肝癌抑制率及其凋亡影响研究

目的:观察新加良附方对移植性小鼠肝癌(H22)生长抑制作用及其对肿瘤组织中Bcl-2和Bax表达影响。方法:建立移植型H22动物模型,并将动物模型随机分模型对照、环磷酰胺(CTX)与新加良附方大、中、小剂量5组。新加良附大、中、小剂量组给药量分别为10g/kg、5g/kg和2.5g/kg;CTX组给药计量为17mg/kg;模型组给予等量无菌生理盐水。连续给药、给水12天处死模型小鼠分离肿瘤,检测肿瘤大小、称重计算肿瘤抑制率,并将肿瘤组织切片,免疫组化法检测Bcl-2和Bax基因。结果:新加良附大剂量组肿瘤抑制率为48.5%,与模型对照组比较,有统计学意义(P<0.01);新加良附大、中剂量可降低肿瘤组织中Bcl-2蛋白基因表达,升高Bax蛋白基因表达,与模型组比较,有显著性差异(P<0.01,P<0.05)。结论:新加良附方可抑制H22瘤体生长,且下调Bcl-2蛋白基因表达,上调Bax基因,提示新加良附方在抗肿瘤方面具有进一步深入研究价值。     

孔腔镜肺叶切除及淋巴结清扫术围手术期应用不同剂量氨溴索对肺癌患者的作用研究

摘要 目的：探讨围手术期应用不同剂量氨溴索对行单孔腔镜肺叶切除及淋巴结清扫术的肺癌患者的作用。方法：选取本院2017年1月至2018年12月期间收治的124例肺癌患者作为受试者,结合患者意愿按随机数字表法将受试者分为小剂量组（n=41）、中剂量组（n=41）和大剂量组（n=42）,术前1d开始给予氨溴索静脉滴注,术后持续7d,比较各组患者临床症状、治疗前后的肺功能、炎症因子、T细胞亚群水平变化及不良反应发生率。结果：大剂量组咳痰容易人数所占比例高于小剂量组,痰液稀薄人数所占比例高于中剂量组及小剂量组（P<0.05）。治疗后大剂量组第一秒用力呼吸容积（FEV¹）、FEV¹/用力肺活量（FVC）高于中剂量组、小剂量组（P<0.05）。治疗后各组炎症因子水平均高于治疗前,且随着剂量的升高,C反应蛋白（CRP）、白介素-6（IL-6）、白介素-8（IL-8）水平呈降低的趋势（P<0.05）。随着剂量的升高,治疗后的 CD3⁺、CD4⁺、CD4⁺/CD8⁺均呈升高趋势,CD8⁺呈降低趋势（P<0.05）。各组不良反应发生率比较无统计学差异（P>0.05）。结论：肺癌患者行单孔腔镜肺叶切除及淋巴结清扫术围手术期应用120mg氨溴索,可加快患者术后恢复,保护患者肺功能,抑制炎症反应,改善患者的免疫功能和临床症状。     

CD4+CD25+FOXP3+ T cells,Foxp3 gene and protein expression contribute to antiasthmatic effects of San’ao decoction in mice model of asthma

ObjectiveSan’ao decoction (SAD) is a commonly used traditional combinatorial formula composed of Herba Ephedrae, Radix Glycyrrhizae and Amygdalus Communis Vas. Early studies showed that in the OVA sensitization asthmatic mice model its compatibility could lower airway reactivity and airway inflammatory cell infiltration. Based on the above results, this study mainly discussed San’ao decoction's immunomodulatory effects on Tregs.MethodsUPLC–PDA–TOF-MS was applied to analyze chemicals of SAD, and under the optimized chromatographic and MS condition, the major components in SAD were well separated and detected within 22 min. An asthma model was established in BALB/c mice that were sensitized and challenged with ovalbumin. After 2 weeks’ treatment, peripheral blood and bronchoalveolar lavage fluid (BALF) were assessed for inflammatory cell counts; histological change of lung tissue were detected; flow cytometry detection of splenic CD4⁺CD25⁺Foxp3⁺ Treg cells of the mice were counted; Foxp3 expression in lung tissues were examined as well.Results22 Peaks signal chemical components in SAD were identified by UPLC–QTO-MS method. In terms of the percentage of eosinophile in peripheral blood and bronchoalveolar lavage fluid (BALF), SAD groups were significantly lower (p < 0.01) than model group. Compared with model group, lung histological changes of SAD groups were reduced; the proportion of CD4⁺CD25⁺Foxp3⁺ Treg cells in CD4⁺ cells of asthmatic mice also decreased; SAD significantly increased the proportion of CD4⁺CD25⁺Foxp3⁺ Treg cells and promoted Foxp3 expression in a mouse model of asthma.ConclusionThese results suggest that the antiasthmatic effects of SAD are at least partially associated with CD4⁺CD25⁺Foxp3⁺ Treg cells.     

Recruitment of human cord blood-derived endothelial colony-forming cells to sites of tumor angiogenesis

Background aimsEndothelial progenitor cells (EPCs) specifically home to sites of malignant growth, rendering them attractive for anti-cancer therapies. Data are conflicting on the phenotype and quantitative contribution toward tumor angiogenesis based on differing culture assays to outgrow EPCs. To evaluate the origin and early phenotype of EPCs and to define a population with enhanced tumor-targeting capacity, we evaluated a hierarchy of cord blood-derived EPCs modeling the multi-step nature of tumor homing.MethodsCD34⁺ mononuclear cells were isolated from fresh cord blood and cultured to derive endothelial colony-forming cells (ECFCs). Human umbilical vein endothelial cells (HUVECs) served as control. Using intra-vital microscopy, the recruitment was analyzed in mice bearing C6 xenografts. Adhesion, migration, transmigration and differentiation were further addressed.ResultsWithin the primary passage, ECFCs underwent a rapid maturation from a CD45⁺ and CD31⁺ phenotype to a CD45^? and endothelial marker positive phenotype. Assessing in vivo tumor recruitment, ECFCs had the highest activity in all steps analyzed. In vitro, ECFCs demonstrated significantly higher adhesion under static and flow conditions. Similarly, ECFCs exhibited highest migratory and trans-migratory activity toward tumor-conditioned medium. On subcutaneous implantation, only ECFCs formed blood vessels covered with perivascular cells, similar to HUVECs.ConclusionsOur study indicates that ECFCs emerge from a CD45⁺ and CD31⁺ progenitor and rapidly mature in culture. ECFCs have a significantly higher potential for tumor targeting than non-cultured CD34⁺ cells and HUVECs. They are ideal candidates for future cell-based anti-cancer therapies.     

Gansui-Banxia Decoction extraction inhibits MDSCs accumulation via AKT /STAT3/ERK signaling pathways to regulate antitumor immunity in C57bl/6 mice

BackgroundGansui-Banxia Decoction (GSBXD) is a classic formula of traditional Chinese medical (TCM) sage Zhang Zhongjing to treat stagnation of evil heat and obstruction of qi. At present GSBXD is wildly used to treat cancerous ascites, pleural effusion, peritoneal effusion, pericardial effusion, cranial cavity effusion and several types of cancers, such as hepatocellular carcinoma (HCC) and esophageal cancer. Myeloid-derived suppressor cells (MDSCs) are a kind of immature and heterogeneous cells which can suppress lymphocytes activation by forming a suppressive environment. MDSCs accumulation in peripheral blood and tumors are closely related to the cancer stage and low survival rate of clinical patients. The antitumor immune effect of GSBXD has not received widespread attention.PurposeTo investigate the effects of GSBXD on MDSCs accumulation and the mediators including AKT/STAT3/ERK signaling pathways.MethodsThe chemical components of GSBXD were analyzed by UHPLC-MS, and the putative pathways of GSBXD based on Network pharmacology were predicted. Mice were vaccinated with Hepatoma 22 (H22) to establish tumor growth model, which were then administrated with GSBXD ethanol extraction (0.49 mg/kg/day, 1.75 mg/kg/day), sorafenib (60 mg/kg) or saline for 14 days. The cell morphology was evaluated by hematoxylin and eosin (H&E) staining, and immunity cells were determined through flowcytometry analysis. The levels of cytokines production in blood were evaluated by using ELISA kits. STAT3, ERK and AKT/mTOR signaling transduction associated proteins were determined by Western blot.ResultsGSBXD could inhibit tumor growth and splenomegaly in H22 tumor model mice. Importantly, GSBXD reduced MDSCs accumulation and differentiation, and inhibited proliferation of F4/80⁺ CD11b⁺ macrophages and apoptosis of T cells and B cells, and increased the percentage of CD 3⁻ NK1.1⁺ NK cells. To better understand the active component of GSBXD, the ethanol-extraction powdered GSBXD was prepared and analyzed by UHPLC-MS. Combined with these main chemical compounds, we predicted that the anti-tumor effect of GSBXD mainly mediated PI3K-AKT and RAS-MAPK signal pathways based on Network Pharmacology. Western blot analysis of tumor tissues and MDSCs cells demonstrated that phosphorylation of AKT, ERK and STAT3 were significantly reduced, specially the activation of ERK. The levels of IL-1β and IFN-γ were significantly decreased by ELISA analysis.ConclusionGSBXD exhibited antitumor immune activity by reducing the accumulation of MDSCs in vivo, which is possible via down-regulation of AKT/STAT3/ERK signaling pathway and suppression of IL-1β and IFN-γ.     

吉非替尼联合PC化疗方案对表皮生长因子受体突变阳性晚期肺腺癌患者免疫功能、凋亡因子和肿瘤标志物的影响

摘要 目的：探讨吉非替尼联合铂类加环磷酰胺（PC）化疗方案对表皮生长因子受体（EGFR）突变阳性晚期肺腺癌患者免疫功能、凋亡因子和肿瘤标志物的影响。方法：选取南通大学附属肿瘤医院2018年3月~2020年3月期间收治的92例EGFR阳性晚期肺腺癌患者,根据随机数字表法分为对照组（PC化疗）和实验组（吉非替尼联合PC化疗）,各为46例。观察两组疗效、肿瘤标志物、免疫功能、凋亡因子变化情况、肿瘤无进展生存时间（PFS）、总生存时间（OS）和不良反应发生率。结果：实验组的客观缓解率、疾病控制率均高于对照组（P<0.05）。两组治疗后血清癌胚抗原（CEA）、细胞角蛋白-19片段（CYFRA21-1）、鳞状细胞癌抗原（SCC-Ag）水平较治疗前均下降,且实验组较对照组低（P<0.05）。治疗后两组CD8⁺升高,但实验组较对照组低;而治疗后CD3⁺、CD4⁺、CD4⁺/CD8⁺均下降,但实验组较对照组高（P<0.05）。两组治疗后血清Livin水平较治疗前下降,且实验组低于对照组（P<0.05）,两组治疗后血清PDCD5、P53、Bax水平较治疗前均升高,且实验组均高于对照组（P<0.05）。两组不良反应发生率组间对比无明显差异（P>0.05）。实验组的PFS、OS高于对照组（P<0.05）。结论：吉非替尼联合PC化疗方案治疗EGFR突变阳性晚期肺腺癌患者,可调节血清凋亡因子和肿瘤标志物水平,有效改善患者的免疫功能和预后。